Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Haemonetics Co. (NYSE:HAE) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $101.67.

A number of analysts have recently commented on HAE shares. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC dropped their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday, February 7th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. Raymond James restated a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the company. Vise Technologies Inc. grew its holdings in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock worth $221,000 after acquiring an additional 225 shares during the period. Waverly Advisors LLC boosted its position in shares of Haemonetics by 17.0% during the 4th quarter. Waverly Advisors LLC now owns 12,769 shares of the medical instruments supplier’s stock valued at $997,000 after purchasing an additional 1,857 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of Haemonetics by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier’s stock valued at $50,223,000 after purchasing an additional 152,042 shares in the last quarter. ProShare Advisors LLC grew its stake in Haemonetics by 40.7% during the fourth quarter. ProShare Advisors LLC now owns 16,486 shares of the medical instruments supplier’s stock worth $1,287,000 after purchasing an additional 4,771 shares during the period. Finally, Nomura Holdings Inc. bought a new stake in Haemonetics in the fourth quarter worth approximately $519,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 1.9 %

Shares of Haemonetics stock opened at $67.23 on Thursday. The firm has a market capitalization of $3.38 billion, a PE ratio of 26.47, a price-to-earnings-growth ratio of 1.11 and a beta of 0.39. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm’s 50 day moving average is $70.18 and its 200 day moving average is $75.83. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.